In the latest high-profile deal for gene therapies, Roche has agreed to acquire Spark Therapeutics for approximately US$4.8 B in cash. Roche gains Spark’s growing portfolio spanning haemophilia, retinal diseases, lysosomal storage disorders and neurodegenerative diseases. Spark made history in December 2018 when its one-time treatment, Luxturna™ (voretigenene parvovec), was the first-ever gene therapy to be approved by the US FDA for a genetic disease.